| Active substance | nivolumab |
| Holder | BMS |
| Status | Closed |
| Indication | first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a CPS ≥ 5 in combination with fluoropyrimidine- and platinum-based chemotherapy |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/08/2022 |